Clinical Focus

  • Medical Oncology

Academic Appointments

Professional Education

  • Board Certification: American Board of Internal Medicine, Medical Oncology (2014)
  • Fellowship: UT MD Anderson Cancer Center Hematology and Oncology Fellowship (2012) TX
  • Fellowship: UT MD Anderson Cancer Center Hematology and Oncology Fellowship (2011) TX
  • Residency: Case Western Reserve University MetroHealth Internal Medicine Residency (2008) OH
  • Medical Education: Sri Ramachandra Institute of Higher Education (2002) India

Contact

  • Clinical (Primary)  Stanford Medical Oncology 875 Blake Wilbur 2nd Floor Palo Alto, CA 94305 (650) 724-3556 (fax)

Additional Clinical Info

Additional Info

Clinical Trials

  • A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors Recruiting

    This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

    View full details

  • Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors Recruiting

    RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer treatments including monotherapy and in combination with other cancer treatments including immunotherapy or chemotherapy. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in combination with pembrolizumab or other approved anticancer therapies or as a monotherapy in subjects with advanced unresectable, recurrent or metastatic tumors. The phase 1a (dose escalation phase) has been completed. The Phase 1b expansion phase of the study has been increased in size and scope.

    View full details

  • Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors Recruiting

    This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

    View full details

  • Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors Recruiting

    The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of GS-2121 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.

    View full details

  • Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Not Recruiting

    The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.

    Stanford is currently not accepting patients for this trial.

    View full details